08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

Actavis Inc., Alkem Laboratories, Amerigen Pharmaceuticals Ltd., Forest Laboratories, Glenmark, Hetero Drugs Ltd., Indchemie Health Specialties Pvt. Ltd., Torre

Forest settled two lawsuits that alleged the generic companies' ANDAs for generic versions of hypertension drug Bystolic nebivolol infringed U.S. Patent No. 6,545,040. In March 2012, Forest filed Forest Laboratories Inc. et al v....
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

Alkem Laboratories, Forest Laboratories, Indchemie Health Specialties Pvt. Ltd., Torrent cardiovascular news

Forest and the generics companies settled a March suit claiming ANDAs from the companies for their generic versions of hypertension drug Bystolic nebivolol infringes Forest's U.S. Patent No. 6,545,040. The patent covers methods of...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Company News

Watson Laboratories Inc., Alkem Laboratories, Amerigen Pharmaceuticals Ltd., Forest Laboratories, Glenmark, Hetero Drugs, Indchemie Health Specialties Pvt. Ltd.

Forest and Johnson & Johnson's Janssen Pharmaceutica N.V. unit filed suit against Amerigen, Glenmark, Hetero Drugs, Torrent and Watson in the U.S. District Court for the District of Delaware claiming ANDAs for generic versions of...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Eprotirome: Phase III started

Karo Bio began a double-blind, placebo-controlled, international Phase III trial to evaluate eprotirome daily in 630 patients for 2 years. Alkem Laboratories Ltd. (Mumbai, India) has exclusive rights from Karo Bio to commercialize eprotirome...
07:00 , May 2, 2011 |  BC Week In Review  |  Company News

Alkem Laboratories, Karo Bio deal

Alkem received exclusive rights to commercialize Karo Bio's metabolic candidate eprotirome in India and other undisclosed Asia-Pacific and African markets. Alkem plans to conduct an Indian Phase III trial of the thyroid hormone receptor...
07:00 , May 2, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

BTG plc (LSE:BGC) gained 4.90p to 248.4p last week after FDA approved an NDA from Centocor Ortho Biotech Inc. for Zytiga abiraterone acetate in combination with prednisone to treat metastatic, castration-resistant prostate cancer (CRPC) in...
23:54 , Apr 26, 2011 |  BC Extra  |  Company News

Karo Bio, Alkem in deal for eprotirome

Karo Bio AB (SSE:KARO) granted Alkem Laboratories Ltd. (Mumbai, India) exclusive rights to commercialize metabolic candidate eprotirome in India and other Asia-Pacific and African markets. Alkem plans to conduct an Indian Phase III trial of...
07:00 , Oct 2, 2006 |  BC Week In Review  |  Company News

Gilead, Alkem Laboratories Ltd., Aurobindo, FDC Ltd., J.B. Chemicals and Pharmaceuticals Ltd., Matrix Laboratories Ltd., Medchem International, Ranbaxy, Shasun

GILD granted the eight Indian companies non-exclusive licenses to distribute and manufacture generic versions of GILD's HIV drug Viread tenofovir in 95 low-income countries, including India. The licensees join three Indian companies that acquired...